Ocular Therapeutix (OCUL) Interest Coverage Ratio (2013 - 2026)
Ocular Therapeutix (OCUL) recorded quarterly Interest Coverage Ratio of 33.61 in Q1 2026, down 36.45% quarter-over-quarter from 24.63 in Q4 2025, and down 56.92% on a YoY basis from 78.02 in Q1 2025.
Ocular Therapeutix (OCUL) Interest Coverage Ratio (2013 - 2026) Analysis & Trends
Ocular Therapeutix's Interest Coverage Ratio history runs 14 years deep, the most recent figure standing at 33.61 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 56.92% year-over-year to 33.61; the TTM figure through Mar 2026 stood at 25.75 (down 57.87% YoY), while the FY2025 annual figure was 22.82, down 80.32% from the prior year.
- Interest Coverage Ratio was 33.61 for Q1 2026 at Ocular Therapeutix, down from 24.63 in the prior quarter.
- In the past five years, Interest Coverage Ratio ranged from a high of 4.83 in Q4 2023 to a low of 33.61 in Q1 2026.
- Historically, Interest Coverage Ratio has averaged 15.02 across 5 years, with a median of 12.75 in 2023.
- The sharpest annual moves came in 2023 and 2024: Interest Coverage Ratio surged 53.92% in 2023, then tumbled 237.12% in 2024.
- A 5-year view of Interest Coverage Ratio shows it stood at 10.48 in 2022, then soared by 53.92% to 4.83 in 2023, then plunged by 237.12% to 16.28 in 2024, then tumbled by 51.28% to 24.63 in 2025, then tumbled by 36.45% to 33.61 in 2026.
- The last three Interest Coverage Ratio figures came in at 33.61 (Q1 2026), 24.63 (Q4 2025), and 22.88 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Ocular Therapeutix | 2.12 Bn | 2.12 Bn | 9.46 Mn | -33.61 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.61 |
| Dec 31, 2025 | -24.63 |
| Sep 30, 2025 | -22.88 |
| Jun 30, 2025 | -22.43 |
| Mar 31, 2025 | -21.42 |
| Dec 31, 2024 | -16.28 |
| Sep 30, 2024 | -14.27 |
| Jun 30, 2024 | -13.64 |
| Mar 31, 2024 | -7.80 |
| Dec 31, 2023 | -4.83 |
| Sep 30, 2023 | -5.61 |
| Jun 30, 2023 | -10.33 |
| Mar 31, 2023 | -12.75 |
| Dec 31, 2022 | -10.48 |
| Sep 30, 2022 | -11.99 |
| Jun 30, 2022 | -11.74 |
| Mar 31, 2022 | -10.60 |
| Dec 31, 2021 | -10.74 |
| Sep 30, 2021 | -11.78 |
| Jun 30, 2021 | -12.22 |